UroGen Pharma Ltd [URGN] stock is trading at $7.37, up 43.39%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The URGN shares have gain 73.82% over the last week, with a monthly amount drifted -27.17%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
UroGen Pharma Ltd [NASDAQ: URGN] stock has seen the most recent analyst activity on May 22, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Scotiabank started tracking the stock with Sector Outperform rating on April 16, 2025, and set its price target to $23. Guggenheim started tracking the stock assigning a Buy rating and suggested a price target of $40 on August 22, 2024. Jefferies downgraded its rating to a Hold and reduced its price target to $10 on February 08, 2023. Berenberg started tracking with a Buy rating for this stock on April 27, 2022, and assigned it a price target of $20. In a note dated April 16, 2020, H.C. Wainwright reiterated an Buy rating on this stock and boosted its target price from $53 to $57.
UroGen Pharma Ltd [URGN] stock has fluctuated between $3.42 and $20.70 over the past year. Currently, Wall Street analysts expect the stock to reach $38.6 within the next 12 months. UroGen Pharma Ltd [NASDAQ: URGN] shares were valued at $7.37 at the most recent close of the market. An investor can expect a potential return of 423.74% based on the average URGN price forecast.
Analyzing the URGN fundamentals
UroGen Pharma Ltd [NASDAQ:URGN] reported sales of 91.87M for the trailing twelve months, which represents a growth of 7.84%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.18%, Pretax Profit Margin comes in at -1.47%, and Net Profit Margin reading is -1.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -974.87 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.65 points at the first support level, and at 3.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.67, and for the 2nd resistance point, it is at 9.97.
Ratios To Look Out For
For context, UroGen Pharma Ltd’s Current Ratio is 5.65. As well, the Quick Ratio is 5.47, while the Cash Ratio is 2.48. Considering the valuation of this stock, the price to sales ratio is 3.70.
Transactions by insiders
Recent insider trading involved Schoenberg Mark, Chief Medical Officer, that happened on Jan 31 ’25 when 4551.0 shares were sold. General Counsel, Smith Jason Drew completed a deal on Jan 31 ’25 to sell 7379.0 shares. Meanwhile, Chief Medical Officer Schoenberg Mark sold 859.0 shares on Sep 09 ’24.
